Medication-Assisted Treatment (MAT) provides an opportunity to address opioid addiction among justice-involved individuals, an often difficult to reach population. This potential has been increasingly recognized by agencies, policymakers and pharmaceutical companies. The result has been a marked increase in the number of drug courts, prisons and agencies in which MAT, notably with long-acting injectable medications, is offered. While this is a positive development, ensuring that vulnerable individuals are in a position voluntarily participation within the complex criminal justice environment is necessary. The unequal authority and agency inherent in the nature of these environments should be recognized. Therefore, rigorous protections, mirroring the goals of the consent processes required for medical or sociobehavorial research, should be employed when MAT is offered to protect individual autonomy.
Notice:
The National Institute of Corrections is currently assessing its website and materials in accordance with recent Executive Orders and related guidance. During this review, some of NIC’s webpages and publications may be temporarily unavailable. Please revisit this web page for updates.
Medication-Assisted Treatment (MAT) in Criminal Justice Settings as a Double-Edged Sword: Balancing Novel Addiction Treatments and Voluntary Participation
Notice about external resources
These links are being provided as a convenience and for informational purposes only; they do not constitute an endorsement or an approval by the National Institute of Corrections (NIC) of any of the products, services or opinions of the corporation or organization or individual. NIC bears no responsibility for the accuracy, legality or content of the external site or for that of subsequent links. Contact the external site for answers to questions regarding its content.
- Created:Updated: